Panna Sharma | President and CEO |
David Margrave | CFO |
Nicole Leber | Investor Relations |
John Vandermosten | Zacks Research |
Michael King | EF Hutton |
[Call Start Abruptly] shortly after the call. We issued a press release after market closed today | summarizing our financial results and progress across the company for the third quarter of 2022. A copy of this release is available through our Web site at lanternpharma.com - where you will also find a link to the slides that management will be referencing on today's call. |
I would like to remind everyone that remarks about future expectations, performance, estimates and prospects constitute forward-looking statements for purposes of Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Lantern Pharma cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated. A number of factors could cause actual results to differ materially from those indicated by forward-looking statements, including the impact of the COVID-19 pandemic, results of clinical trials and the impact of competition. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements can be found in our Annual Report on Form 10-K for the year ended December 31, 2021, which is on file with the SEC and available on our Web site. Forward-looking statements made on this conference call are as of today, Monday, November 7, 2022 and Lantern Pharma does not intend to update any of these forward-looking statements to reflect events from circumstances that occur after today, unless required by law. A webcast replay of the conference call and webinar will be available on Lantern's Web site. On today's webcast, we have Lantern Pharma's CEO, Panna Sharma | and CFO, David Margrave. Panna will start things off in a minute with an overview of Lantern's operational highlights and business activity, after which, David will discuss our financial results. This will be followed by some concluding comments from Panna, and then we'll open up the call for Q&A. |
I'd now like to turn the call over to Panna Sharma | President and CEO of Lantern Pharma. Panna - please go ahead. |
Thank you, Nicole. Good afternoon, everyone. And welcome to our third quarter 2022 earnings call. Thank you for joining us this afternoon to hear about our third quarter results and corporate progress at Lantern. Lantern Pharma is at the leading edge of leveraging artificial intelligence, machine learning algorithms, biomarker, clinical, genomic and drug response data to transform the costs, compress the timelines and derisk oncology drug discovery, as well as oncology drug development.